financetom
Business
financetom
/
Business
/
Lomiko Metals Buying Yellow Fox Project From Metals Creek
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lomiko Metals Buying Yellow Fox Project From Metals Creek
Jan 22, 2025 7:24 AM

10:02 AM EST, 01/22/2025 (MT Newswires) -- Lomiko Metals (LMR.V) overnight Tuesday entered into an agreement with Metals Creek Resources (MEK.V) to buy all of 28 mineral claims which form the Yellow Fox project.

MEK was at last look up $0.005 or 20% to 0.03 on the news.

A statement noted the claims involved consist of 28 contiguous claim units in two licenses for a total of 7 square km. The acquisition agreement is subject to approval by the TSX Venture Exchange (TSXV), with the closing date expected on or about Feb. 28.

"We are pleased to add another critical mineral, antimony, to our portfolio with upside potential in silver and gold. We also welcome Metals Creek as a shareholder of Lomiko and look forward to working with Metals Creek in the long term," said Lomiko Chief Executive Gordana Slepcev. "We are also pleased to be advancing the La Loutre graphite project as planned for bulk sample permitting and evaluating our regional graphite claims for the next steps."

The Yellow Fox project is an early exploration project with positive early results including returned samples anomalous in gold (Au), antimony (Sb), lead (Pb), zinc (Zn) and silver (Ag) referred to as the "Yellow Fox Showing".

Pursuant to the deal, Lomiko will buy all of Metal Creek's right, title and interest in and to the option interests, with Metals Creek retaining a 2% NSR royalty. Lomiko will pay cash totaling $64,750 and will issue common shares of the company for $328,375, at $0.13 apiece which will be subject to the statutory hold period.

The company intends to review existing data and potentially initiate fieldwork in the spring. Expansion of the lines and additional lines to the south are warranted if the soil sampling program is proven effective, the company added.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Vistra Unusual Options Activity For March 10
Vistra Unusual Options Activity For March 10
Mar 10, 2025
Deep-pocketed investors have adopted a bullish approach towards Vistra ( VST ) , and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in VST usually suggests something big is about to happen. We gleaned this information from...
BRIEF-Avalon Globocare and Yoov to merge
BRIEF-Avalon Globocare and Yoov to merge
Mar 10, 2025
March 10 (Reuters) - Avalon Globocare Corp ( ALBT ): * AVALON GLOBOCARE AND YOOV, A LEADING BUSINESS AI AUTOMATION SOLUTIONS PROVIDER, ENTER INTO MERGER AGREEMENT * AVALON GLOBOCARE CORP ( ALBT ) - NEW COMBINED COMPANY TO TRADE UNDER NASDAQ SYMBOL 'YOOV' * AVALON GLOBOCARE CORP ( ALBT ) - PHIL WONG TO BECOME CHAIRMAN, CEO, AND PRESIDENT POST-MERGER...
Veren Soars On Whitecap Merger Deal: Details
Veren Soars On Whitecap Merger Deal: Details
Mar 10, 2025
Veren Inc. ( VRN ) shares are trading higher on Monday after the company inked a merger deal with Whitecap Resources Inc. for an all-share transaction valued at around C$15 billion ($10.4 billion), including net debt. As per the terms of the deal, Veren ( VRN ) shareholders will receive 1.05 common shares of Whitecap for each Veren ( VRN...
Genmab Says Johnson & Johnson Declines Global License Option for HexaBody-CD38; Shares Fall
Genmab Says Johnson & Johnson Declines Global License Option for HexaBody-CD38; Shares Fall
Mar 10, 2025
10:58 AM EDT, 03/10/2025 (MT Newswires) -- Genmab ( GMAB ) said Monday that Johnson & Johnson ( JNJ ) has chosen not to exercise its option for a global license to develop, produce, and market HexaBody-CD38. Although the initial HexaBody-CD38 clinical data demonstrated strong efficacy, Genmab ( GMAB ) has decided not to proceed with further development after evaluating...
Copyright 2023-2026 - www.financetom.com All Rights Reserved